Alphabet, GeneScience, AstraZeneca, Shire, Novartis, Ping An, KPC and Stevanato are in line for exits after the drug delivery technology developer filed to go public.
US-based biologics delivery technology developer Rani Therapeutics has filed to raise up to $100m in an initial public offering that would allow several corporate investors to exit.
Rani is developing a capsule called the RaniPill, which would allow for biologics to be delivered orally to patients, instead of through subcutaneous or IV injection.
The IPO proceeds have been earmarked for research and development and the advancement of Rani’s product pipeline, as well as growing its manufacturing capabilities and paying…
